Founded with a mission to restore immune balance in patients receiving solid organ transplants, TRACT Therapeutics is pioneering personalized medical solutions. The company’s core product, TregCel™, utilizes a patient's own regulatory T cells, expanded in a lab and re-infused to establish immune tolerance. This innovative approach aims to improve outcomes for transplant patients and those suffering from autoimmune disorders, focusing on personalized and effective treatments.
TRACT Therapeutics has attracted attention from notable investors and experts in the biotech industry. The company’s advancements have been recognized for their potential to significantly impact transplant medicine and autoimmune disease management. By leveraging cutting-edge science and technology, TRACT Therapeutics is poised to make substantial contributions to patient care and the broader medical community.
